All In Biotech

Drug Trial Radar · NCT01595061

Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva

A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)

Last checked: Nov 19, 2026Latest source record: Dec 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownResults posted on the registry

Status

Status unknown

Enrollment

57

Actual

Start

Jul 2, 2012

Primary completion

Sep 23, 2020

Study completion Sep 23, 2022

Sponsor

Lead sponsor
Gynecologic Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
May 9, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well radiation therapy works when given with gemcitabine hydrochloride and cisplatin work in treating patients with squamous cell cancer of the vulva that has spread from where it started to nearby tissue or lymph nodes. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving radiation therapy together with gemcitabine hydrochloride and cisplatin may kill more tumor cells.

Conditions

  • Stage III Vulvar Cancer AJCC v7
  • Stage IIIA Vulvar Cancer AJCC v7
  • Stage IIIB Vulvar Cancer AJCC v7
  • Stage IIIC Vulvar Cancer AJCC v7
  • Stage IVA Vulvar Cancer AJCC v7
  • Vulvar Squamous Cell Carcinoma

Interventions

  • CisplatinDrug

    Given IV

  • Gemcitabine HydrochlorideDrug

    Given IV

  • Intensity-Modulated Radiation TherapyRadiation

    Undergo IMRT

  • Therapeutic Conventional SurgeryProcedure

    Undergo local core biopsy or surgical excision

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Pathologic ResponseTime frame: 6 -8 weeks after completion of chemo-radiation

Locations

193 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Hartford Hospital

    Hartford, Connecticut

  • The Hospital of Central Connecticut

    New Britain, Connecticut

  • Beebe Medical Center

    Lewes, Delaware

  • Christiana Gynecologic Oncology LLC

    Newark, Delaware

  • Delaware Clinical and Laboratory Physicians PA

    Newark, Delaware

  • Helen F Graham Cancer Center

    Newark, Delaware

  • Medical Oncology Hematology Consultants PA

    Newark, Delaware

  • Christiana Care Health System-Christiana Hospital

    Newark, Delaware

  • Beebe Health Campus

    Rehoboth Beach, Delaware

  • TidalHealth Nanticoke / Allen Cancer Center

    Seaford, Delaware

  • Christiana Care Health System-Wilmington Hospital

    Wilmington, Delaware

  • Augusta University Medical Center

    Augusta, Georgia

  • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler

    Savannah, Georgia

  • The Cancer Center of Hawaii-Pali Momi

    ‘Aiea, Hawaii

  • Queen's Medical Center

    Honolulu, Hawaii

  • University of Hawaii Cancer Center

    Honolulu, Hawaii

  • The Cancer Center of Hawaii-Liliha

    Honolulu, Hawaii

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho

  • Saint Luke's Cancer Institute - Twin Falls

    Twin Falls, Idaho

  • Rush - Copley Medical Center

    Aurora, Illinois

  • Saint Joseph Medical Center

    Bloomington, Illinois

  • Illinois CancerCare-Bloomington

    Bloomington, Illinois

  • Illinois CancerCare-Canton

    Canton, Illinois

  • Memorial Hospital of Carbondale

    Carbondale, Illinois

  • SIH Cancer Institute

    Carterville, Illinois

Showing 40 of 193 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.